Report in English with a Dutch summary (KCE reports 45A)

More documents

Recommendations

Info

226 Screening for Colorectal Cancer KCE reports vol.45 159. Schulmann K, Brasch FE, Kunstmann E, Engel C, Pagenstecher C, Vogelsang H, et al. HNPCC-associated small bowel cancer: clinical and molecular characteristics. Gastroenterology. 2005;128(3):590-9. 160. Velayos FS, Allen BA, Conrad PG, Gum J, Jr., Kakar S, Chung DC, et al. Low rate of microsatellite instability in young patients with adenomas: reassessing the Bethesda guidelines. American Journal of Gastroenterology. 2005;100(5):1143-9. 161. Potter JD. Colorectal cancer: molecules and populations. J Natl Cancer Inst. 1999;91(11):916-32. 162. Huang SC, Lavine JE, Boland PS, Newbury RO, Kolodner R, Pham TT, et al. Germline characterization of early-aged onset of hereditary non-polyposis colorectal cancer. Journal of Pediatrics. 2001;138(5):629-35. 163. Christensen M, Katballe N, Wikman F, Primdahl H, Sorensen FB, Laurberg S, et al. Antibody-based screening for hereditary nonpolyposis colorectal carcinoma compared with microsatellite analysis and sequencing. Cancer. 2002;95(11):2422-30. 164. Jo W-S, Chung DC. Genetics of hereditary colorectal cancer. Seminars in Oncology. 2005;32(1):11-23. 165. Marroni F, Pastrello C, Benatti P, Torrini M, Barana D, Cordisco EL, et al. A genetic model for determining MSH2 and MLH1 carrier probabilities based on family history and tumor microsatellite instability. Clinical Genetics. 2006;69(3):254-62. 166. Stormorken AT, Hoff G, Norstein J, Bowitz-Lothe IM, Hanslien E, Grindedal E, et al. Estimated prevalence of hereditary cancers and the need for surveillance in a Norwegian county, Telemark. Scand J Gastroenterol. 2006;41(1):71-9. 167. Ramsey SD, Yoon P, Moonesinghe R, Khoury MJ. Population-based study of the prevalence of family history of cancer: implications for cancer screening and prevention. Genetics in Medicine. 2006;8(9):571-5. 168. Mitchell RJ, Campbell H, Farrington SM, Brewster DH, Porteous MEM, Dunlop MG. Prevalence of family history of colorectal cancer in the general population. British Journal of Surgery. 2005;92(9):1161-4. 169. Field MJL, K.N.,. Guidelines for clinical practice. From development to use. Washington D.C.: National academy press; 1992. 170. University of Oxford. Centre for Evidence-Based Medicine. http://www.cebm.net/. 2006. 171. Murphy MK, Black NA, Lamping DL, McKee CM, Sanderson CF, Askham J, et al. Consensus development methods, and their use in clinical guideline development. Health Technology Assessment (Winchester, England). 1998;2(3):i-iv. 172. Lohr KN, Carey TS. Assessing "best evidence": issues in grading the quality of studies for systematic reviews. Joint Commission Journal on Quality Improvement. 1999;25(9):470-9. 173. AHRQ. Publication No. 02-E015: Systems to Rate the Strength of Scientific Evidence. 2002. 174. AGREE collaboration. Appraisal of Guidelines Research and Evaluation (AGREE) Instrument. 2001. 175. NICE. The guideline development process - an overview for stakeholders, the public and the NHS (second edition). 2006. 176. SIGN. SIGN 50: A guideline developers' handbook. 2001;Publication No.50. 177. NICE. The guidelines manual 2006. 2006. 178. Woolf SH. Practice guidelines, a new reality in medicine. II. Methods of developing guidelines. Archives of Internal Medicine. 1992;152(5):946-52. 179. ACCP. Recommendations on cancer screening in the European union. Advisory Committee on Cancer Prevention. Eur J Cancer. 2000;36(12):1473-8. 180. ICSI. Colorectal Cancer Screening. http://www.icsi.org/display_file.asp?FileId=148&title=Colorectal%20Cancer%20Scree ning. 2006.
KCE reports vol.45 Screening for Colorectal Cancer 227 181. Barkun AN, Jobin G, Cousineau G, Dube S, Lahaie R, Pare P, et al. The Quebec Association of Gastroenterology position paper on colorectal cancer screening - 2003. Can J Gastroenterol. 2004;18(8):509-19. 182. USPSTF. Screening for colorectal cancer: recommendation and rationale. Ann Intern Med. 2002;137(2):129-31. 183. European Council. Council Recommendation of 2 December 2003 on cancer screening. http://eurlex.europa.eu/LexUriServ/site/en/oj/2003/l_327/l_32720031216en00340038.pdf. 2003. 184. Davila RE, Rajan E, Baron TH, Standards of Practice Committee ASfGE. ASGE guideline: colorectal cancer screening and surveillance. Gastrointest Endosc. 2006;63(4):546-57. 185. Adler M, De Vos M, Dufour A, Janssens J, Laurent S, Melange M, et al. Report on the Belgian consensus meeting on colorectal cancer screening. Acta Gastroenterol Belg. 2005;68(2):239-40. 186. Finnish Medical Society Duodecim. Prevention and screening of colorectal cancer. EBM Guidelines. Evidence-Based Medicine [CD-ROM]. 2005. 187. UMHS. Adult preventive health care: cancer screening. 2004. 188. WGO-OMGE. WGO-OMGE Practice Guideline: Colorectal Cancer Screening and Surveillance. 2004. 189. Kwaliteitsinstituut voor de Gezondheidszorg C-N. Follow-up na poliepectomie - Herziene richtlijn. 2002. 190. BSG, ACPGBI. Guidelines for colorectal cancer screening in high risk groups. 2002. 191. Fisher JA, Fikry C, Troxel AB. Cutting cost and increasing access to colorectal cancer screening: another approach to following the guidelines. Cancer Epidemiol Biomarkers Prev. 2006;15(1):108-13. 192. Boggs BD, Stephens MM, Wallace R. How does colonoscopy compare with fecal occult blood testing as a screening tool for colon cancer? Journal of Family Practice. 2005;54(11):996-7. 193. Collins JF, Lieberman DA, Durbin TE, Weiss DG, Veterans Affairs Cooperative Study G. Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann Intern Med. 2005;142(2):81-5. 194. Pignone M, Saha S, Hoerger T, Mandelblatt J. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137(2):96-104. 195. Ransohoff DF, Lang CA. Screening for colorectal cancer with the fecal occult blood test: a background paper. American College of Physicians. Annals of Internal Medicine. 1997;126(10):811-22. 196. Launoy G, Berchi C. Advantage of immunochemical fecal occult blood test in screening for colorectal cancer. Bulletin du Cancer. 2005;92(10):885-90. 197. Young GP, St John DJB, Winawer SJ, Rozen P, Who, Omed. Choice of fecal occult blood tests for colorectal cancer screening: recommendations based on performance characteristics in population studies: a WHO (World Health Organization) and OMED (World Organization for Digestive Endoscopy) report. American Journal of Gastroenterology. 2002;97(10):2499-507. 198. Federici A, Giorgi Rossi P, Borgia P, Bartolozzi F, Farchi S, Gausticchi G. The immunochemical faecal occult blood test leads to higher compliance than the guaiac for colorectal cancer screening programmes: a cluster randomized controlled trial. J Med Screen. 2005;12(2):83-8. 199. Giorgi Rossi P, Federici A, Bartolozzi F, Farchi S, Borgia P, Guasticchi G. Trying to improve the compliance to colorectal cancer screening: a complex study design for a complex planning question. Contemporary Clinical Trials. 2005;26(3):323-30.
Page 1 and 2:
Health Technology Assessment Colore
Page 3 and 4:
Health Technology Assessment Colore
Page 5 and 6:
KCE reports vol.45A Colorectale Kan
Page 7 and 8:
Page 9:
Page 12 and 13:
2 Screening for Colorectal Cancer K
Page 14 and 15:
Page 16 and 17:
Page 18 and 19:
Page 20 and 21:
10 Screening for Colorectal Cancer
Page 22 and 23:
Page 24 and 25:
Page 26 and 27:
Page 28 and 29:
Page 30 and 31:
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
Page 38 and 39:
Page 40 and 41:
Page 42 and 43:
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
Page 50 and 51:
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187: 176 Screening for Colorectal Cancer
Page 259 and 260: This page is left intentionally bla
Page 261: KCE reports 1. Effectiviteit en kos
show all

Report in English with a Dutch summary (KCE reports 45A)

Create successful ePaper yourself

Delete template?

Save as template?